menu search

U.s. ipo weekly recap: biotech lexeo stumbles after $100 million ipo

Two IPOs are currently scheduled for the week ahead, although some small issuers may join the calendar late. As of 11/2/2023, the Renaissance IPO Inde...

November 4, 2023, 12:21 am

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Oncolytics biotech inc. (oncy) q3 2023 earnings call transcript

Oncolytics biotech Inc. (NASDAQ:ONCY ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Com...

November 3, 2023, 9:05 pm

Taysha gene therapies: tsha-102's potential is a 'buy'

Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS disease...

November 3, 2023, 7:41 pm

Puma biotech (pbyi) q3 earnings beat, revenues lag estimates

Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance....

November 3, 2023, 1:32 pm

Longeveron to report third quarter 2023 results and provide corporate update on november 10, 2023

MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company d...

November 3, 2023, 12:00 pm

This stock just dropped by 15%: is it a buy?

Sanofi's third-quarter results weren't great, and the company announced a business separation. The biotech ...

November 3, 2023, 10:07 am

Puma biotechnology, inc. (pbyi) q3 2023 earnings call transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior D...

November 2, 2023, 10:21 pm

Vir biotechnology, inc. (vir) q3 2023 earnings call transcript

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive...

November 2, 2023, 9:42 pm

Cidara therapeutics provides corporate update and reports third quarter 2023 financial results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapi...

November 2, 2023, 8:15 pm

Puma biotech (pbyi) tops q3 earnings estimates

Puma biotech (PBYI) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Es...

November 2, 2023, 7:32 pm

Moderna ceo discusses earnings and how the company aims to break even by 2026

While boasting a third-quarter revenue beat, biotech firm Moderna (MRNA) reported an overwhelmingly hig...

November 2, 2023, 6:24 pm

Regenxbio: biotech to watch with 2 possible accelerated approval pathways

Regenxbio Inc. is making progress in its pipeline, aiming to have five gene therapies in late-stage testing or approved by 2025. The company's lead ca...

November 2, 2023, 5:33 pm

Pbyi or tech: which is the better value stock right now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Puma biotech ...

November 2, 2023, 12:47 pm

Ocugen to host conference call on thursday, november 9 at 8:30 a.m. et to discuss business updates and third quarter 2023 financial results

MALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, ...

November 2, 2023, 11:30 am

Global microfluidics market to touch us$ 23,739.1 million by 2033, registering an 11.9% cagr | fmi study

The microfluidics industry is poised for remarkable growth in the near future, driven by its diverse applications across healthcare, biotechnology, an...

November 2, 2023, 10:30 am

Molecular partners to present initial data from ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the 65th ash annual meeting and exposition

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (...

November 2, 2023, 2:00 am


Search within

Pages Search Results: